Sartor O, Pal SK. Urological cancer: Abiraterone and its place in the treatment of metastatic CRPC. Nat Rev Clin Oncol. 2012 Nov 13. [Epub ahead of print] (PMID: 23149889)

Yuh BE, Ruel N, Wilson TG, Vogelzang N, Pal SK. Pooled Analysis of Clinical Outcomes with Neoadjuvant Cisplatin and Gemcitabine Chemotherapy for Muscle-Invasive Bladder Cancer. J Urol. 2012 Oct 31. [Epub ahead of print] (PMID: 23123547)

Pal SK, Lewis B, Sartor O. Management of docetaxel failures in metastatic castrate-resistant prostate cancer. Urol Clin North Am. 2012 Nov;39(4):583-91. (PMID: 23084533)

Pal SK, Yamzon J, Sun V, Carmichael C, Saikia J, Ferrell B, Frankel P, Hsu J, Twardowski P, Stein CA, Margolin K. Paclitaxel-Based High-Dose Chemotherapy with Autologous Stem Cell Rescue for Relapsed Germ Cell Tumor: Clinical Outcome and Quality of Life in Long-Term Survivors. Clin Genitourin Cancer. 2012 Oct 10 [Epub ahead of print] (PMID: 23062817)

Carmichael C, Yuh BE, Sun V, Lau C, Hsu J, Saikia J, Liu X, Wilson T, Ferrell B, Pal SK. Quality of Life in Patients With Metastatic Renal Cell Carcinoma: Assessment of Long-Term Survivors. Clin Genitourin Cancer 2012. [Epub ahead of print] (PMID: 23058499)

Mortimer J, Zonder HB, Pal SK. Lessons learned from the bevacizumab experience. Cancer Control. 2012 Oct;19(4):309-16. (PMID: 23037498)

Pal SK, Bergerot PG, Figlin RA Tivozanib : current status and future directions in the treatment of solid tumors. Expert Opin Investig Drugs 2012. [Epub ahead of print] PMID: 23013465

Pal SK, Ruel NH, Wilson TG, Yuh BE. Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer. Clin Genitourin Cancer 2012 Sep 12. [Epub ahead of print] PMID: 22981208

Carmichael C, Lau C, Josephson DY, Pal SK. Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma. Clin Adv Hematol Oncol 2012;10:307-14. PMID: 22706540

Deng J, Liu Y, Lee H, Herrmann A, Zhang W, Zhang C, Shen S, Priceman SJ, Kujawski M, Pal SK, Raubitschek A, Hoon DS, Forman S, Figlin RA, Liu J, Jove R, Yu H. S1PR1-STAT3 Signaling Is Crucial for Myeloid Cell Colonization at Future Metastatic Sites. Cancer Cell. 2012 May 25;21(5):642-54. PMID: 22624714

Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM, Li Y, Nelson RA, Mu B, Onami SH, Wu JJ, Ruel NH, Wilczynski SP, Gao H, Covarrubias M, Figlin RA, Weiss LM, Wu H. Identification of a 4-microRNA Signature for Clear Cell Renal Cell Carcinoma Metastasis and Prognosis. PLoS One. 2012;7(5):e35661. Epub 2012 May 18. PMID: 22623952

Pal SK, Jones JO, Carmichael C, Saikia J, Hsu J, Liu X, Figlin RA, Twardowski P, Lau C. Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: A retrospective analysis. Urol Oncol. 2012 May 17. [Epub ahead of print] PMID: 22608544

Pal SK, Figlin RA. Unraveling the role of hypoxia-inducible factor in renal cell carcinoma: a biological and therapeutic perspective. Cancer Discov. 2011 Aug;1(3):198-9. PMID: 22586568

Pal SK, Stein CA. Prolonged Therapy With Cabazitaxel in an Octogenarian With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2012 May 8. [Epub ahead of print] PMID: 22575202

Pal SK, Williams S, Josephson DY, Carmichael C, Vogelzang NJ, Quinn DI. Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling Paradigm. Mol Cancer Ther 2012 Feb 17. [Epub ahead of print] PMID: 22351744

Bourdeanu L, Frankel P, Yu W, Hendrix G, Pal SK, Badr L, Somlo G, Luu T. Chemotherapy-Induced Nausea and Vomiting in Asian Women with Breast Cancer Receiving Anthracycline-Based Adjuvant Chemotherapy. J Support Oncol 2012 Jan 4. [Epub ahead of print] (PMID: 22222249)

Bourdeanu L, Twardowski P, Pal SK. Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma. Clin J Oncol Nurs 2011 Oct;15(5):513-7. (PMID: 21951737)

Xin H, Herrmann A, Reckamp K, Zhang W, Pal SK, Hedvat M, Zhang C, Liang W, Scuto A, Weng S, Morosini D, Cao ZA, Zinda M, Figlin R, Huszar D, Jove R, Yu H. Anti-angiogenic and anti-metastatic activity of JAK inhibitor AZD1480. Cancer Res 2011 Sep 15. [Epub ahead of print] (PMID 21920898)

Torrey R, Spiess PE, Pal SK, Josephson D: Role of surgery for locally advanced and metastatic renal cell carcinoma. J Natl Compr Canc Netw 2011 Sep 1;9(9):985-93. (PMID: 21917623)

Vasani D, Josephson DY, Carmichael C, Sartor O, Pal SK: Recent advances in the therapy of castration-resistant prostate cancer: The price of progress. Maturitas 2011 Aug 8. [Epub ahead of print] (PMID: 21831545)

Pal SK, Vogelzang NJ: Managing refractory metastatic renal cell carcinoma: A RECORD spinning on a tilted AXIS. Clin Genitourin Cancer 2011 Aug 2. [Epub ahead of print] (PMID: 21812499)

Pal SK, Vanderwalde A, Hurria A, Figlin RA: Systemic therapies for metastatic renal cell carcinoma in older adults. Drugs Aging 2011 Aug 1;28(8):635-49.

Madan RA, Pal SK, Sartor O, Dahut WL: Overcoming chemotherapy resistance in prostate cancer. Clin Cancer Res 2011 June 15;17(12):3892-902. (PMID 21680545)

Williams SB, Lay AH, Lau CS, Josephson DY, Wilson TG, Choueiri TK, Pal SK: New therapies for castrate-resistant prostate cancer. Expert Opin Pharmacother 2011 Jun 11. [Epub ahead of print] (PMID: 21663529)

Pal SK, Sartor O: Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer. Asian J Androl 2011 May 23. [Epub ahead of print] (PMID 21602834)

Pal SK, Figlin R: Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma. Target Oncol 2011 Apr 12. [Epub ahead of print] (PMID: 21484496)

Vanderwalde AM, Pal SK, Reckamp K: Management of non-small cell lung cancer in the older adult. Maturitas 2011 Apr;68(4):311-21. (PMID: 21295421)

Pal SK, Childs B, Pegram M: Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 2011 Feb;125(3):627-36. (PMID 21161370)

Pal SK, Twardowski P, Sartor O: Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging 2010 Dec; 5:395-402. (PMID: 21152241)

Pal SK, Reckamp KL: Mammalian target of rapamycin, Akt, and phosphatidylinositol 3-kinase signaling. J Thorac Oncol 2010 Dec; 5(12 Suppl 6):S487-9. (PMID: 21102251)

Pal SK, Sartor O: Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer. Maturitas 2011 Feb;68(2):103-5. Epub 2010 Nov 19. (PMID: 21093995)

Pal SK, Kortylewski M, Yu H, Figlin RA: Breaking through a plateau in renal cell carcinoma therapeutics: Development and incorporation of biomarkers. Mol Cancer Ther 2010 Nov; [Epub ahead of print] (PMID: 21078774)

Pal SK, Figlin RA: Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules. Expert Opin Biol Ther 2010 Nov;10(11):1517-20. (PMID: 20955110)

Pal SK, Reckamp K, Yu H, Figlin RA: Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs. 2010 Nov;19(11):1355-66. (PMID: 20846000)

Pal SK, Figlin RA, Yu H: Deciphering the antitumor mechanisms of sunitinib. Cancer Biol Ther 2010 Oct 24;10(7). (PMID: 20716960)

Pal SK, Figlin RA: Treatment options in metastatic renal cell carcinoma: Focus on mTOR inhibitors. Clin Med Insights Oncol 2010; 4:43-53. (PMID: 20711245)

Mortimer JE, Pal SK: Safety considerations for use of bone-targeted agents in patients with cancer. Semin Oncol 2010; 37(Suppl1):S66-72. (PMID: 20682374)

Agrawal K, Onami S, Mortimer JE, Pal SK: Cognitive changes associated with endocrine therapy for breast cancer. Maturitas 2010 Aug 3 [Epub ahead of print] (PMID: 20688441)

Pal SK, Hurria A: Impact of Age, Sex, and Comorbidity on Cancer Therapy and Disease Progression. J Clin Oncol 2010 July 19. [Epub ahead of print] (PMID: 20644100)

Pal SK, Figlin RA: Targeted therapies for renal cell carcinoma: understanding their impact on survival. Target Oncol 2010 July 15. [Epub ahead of print] (PMID: 20632214)

Pal SK, Figlin RA: Pazopanib: carving a niche in a crowded therapeutic landscape. Nat Rev Clin Oncol 2010; 7(7):362-3. (PMID: 20592710)

Pal SK, Figlin RA, Reckamp K: Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol Cacer Ther 2010 Jun 22. [Epub ahead of print] (PMID: 20571071)

Pal SK, Lau SK, Kruper L, et al: Papillary carcinoma of the breast: an overview. Breast Cancer Res Treat 2010 Jun 4. [Epub ahead of print] (PMID: 20524058)

Lee H, Pal SK, Reckamp K, Figlin RA, Yu H. STAT3: A Target to Enhance Antitumor Immune Response. Curr Top Microbiol Immunol. 2010 Jun 2. [Epub ahead of print] (PMID: 20517723)

Pal SK, Figlin RA: Renal cell carcinoma in 2010: Many options with little comparative data. Clin Adv Hematol Oncol 2010; 8(3):191-200. (PMID: 20400934)

Naeim A, Wong FL, Pal SK, Hurria A: Oncologists’ recommendations for adjuvant therapy in hormone-receptor positive breast cancer patients of varying age and health status. Clin Breast Cancer 2010; 10(2):136-43. (PMID: 20353934)

Onami S, Ozaki M, Mortimer J, Pal SK: Male breast cancer: An update in diagnosis, treatment and molecular profiling. Maturitas 2010; 65(4):308-14. (PMID: 20138719)

Pal SK, Katheria V, Hurria A: Evaluating the older patient with cancer: Understanding frailty and the geriatric assessment. CA Cancer J Clin 2010; 60(2):120-32. (PMID: 20173172)

Pal SK, Childs B, Pegram M: Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer. Breast Cancer Res Treat 2010; 119(1):25-32. (PMID: 19795206)

Pal SK, Twardowski P, Josephson DY: Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathways. Maturitas 2009; 64(2):61-6. (PMID: 19733987)

Hurria A, Wong FL, Pal SK, et al: Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER2-positive breast cancer: A survey of oncologists. The Oncologist 2009; 14(9):883-90. (PMID: 19726455)

Pal SK, Mortimer J: Adjuvant chemotherapy for older adults with breast cancer: making the standard a standard. Women’s Health 2009; 5(5):481-4. (PMID: 19702447)

Pal SK, Mortimer J: Triple-negative breast cancer: Novel therapies and new directions. Maturitas 2009; 63(4):269-74. (PMID: 19632796)

Pal SK, Mortimer J: Adjuvant systemic therapy for older adults with early-stage breast cancer. Women’s Health 2009; 5(3):251-62 (PMID: 19392611)

Pal SK, Gupta R, Dosik G, Figlin R: Concomitant renal cell carcinoma and chronic myelogenous leukemia: Utilization of a targeted approach. Current Oncol 2009; 16(2):44-7. (PMID: 19370179)

Pal SK, Reckamp KL, Figlin RA: The role of targeting mammalian target of rapamycin in lung cancer. Clin Lung Cancer 2008; 9(6):340-5. (PMID: 19073516)

Pal SK, Blazer K, Weitzel J, Somlo G: An association between invasive breast cancer and familial idiopathic hyperparathyroidism: A case series and review of the literature. Breast Cancer Res Treat 2008; 114(1):1-5. (PMID: 18500673)

Pal SK, Pegram M: HER2 targeted therapy in breast cancer … beyond Herceptin. Rev Clin Endo Metab Disorders 2007; 8(3):269-77. (PMID: 17899385)

Pal SK, Figlin RA: Mixed epithelial stromal tumor (MEST) of the kidney: a case report and review of the literature. Kidney Cancer J 2007; 5(2):85-86.

Pal SK, Hurria A: Breast cancer in the older patient. Oncological Disease 2007; 1(1):32-34.

Pal SK, Pegram M: Targeting HER2 epitopes. Semin Oncol 2006; 33(4):386-391. (PMID: 16890794)

Pal SK, Pegram M: Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy. Anticancer Drugs 2005; 16(5):483-94. (PMID: 15846113)

Schiller GJ, Said J, Pal SK: Hairy cell leukemia and sarcoidosis: a case report and review of the literature. Leukemia 2003; 17(10):2057-9. (PMID: 14513061)